Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Apr;72(4):827-840.
doi: 10.1007/s00262-022-03283-5. Epub 2022 Sep 9.

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

Marta Español-Rego  1 , Carlos Fernández-Martos  2 , Elena Elez  3 , Carles Foguet  4 , Leire Pedrosa  5 , Nuria Rodríguez  6 , Ana Ruiz-Casado  7 , Estela Pineda  5 , Joan Cid  8 , Raquel Cabezón  1 , Helena Oliveres  5 , Miquel Lozano  8 , Angels Ginés  9   10 , Angeles García-Criado  11 , Juan Ramon Ayuso  11 , Mario Pagés  11 , Miriam Cuatrecasas  12   10 , Ferràn Torres  13 , Timothy Thomson  14   10   15 , Marta Cascante  4   10 , Daniel Benítez-Ribas  16 , Joan Maurel  17   18
Affiliations
Multicenter Study

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

Marta Español-Rego et al. Cancer Immunol Immunother. 2023 Apr.

Abstract

Background: Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects.

Methods: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage.

Results: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways.

Conclusions: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities.

Trial registration: ClinicalTrials.gov NCT03152565.

Keywords: Metabolism; Resistance; Vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
1A. Immune-metabolic signature (IMMETCOLS) baseline expression. 1B. Gene expression pro-immune signature (GEP) baseline expression 1C. Changes in concentrations of cytokines comparing each patient baseline serum with that obtained at day 56 after
Fig. 2
Fig. 2
Correlation of both signatures GEP and IMMETCOLS with response rate (2A and 2B), progression free survival or overall survival (2C, 2D). 2E and 2F. Kaplan–Meier curves for overall survival with GEP and IMMETCOLs signatures
Fig. 3
Fig. 3
Liver biopsies before and after therapy (2-month evaluation) analyzed in both signatures. 3A. Changes in gene expression with IMMETCOLS signature. 3B. Changes in gene expression with GEP signature. 3C. Radiological CT basally and at 2 month therapy
Fig. 4
Fig. 4
A total of 143 genes significantly changed between pre and post-therapy samples. 4A. More critically GO biological processes changed before and after therapy. 4B. Top 20 genes down-regulated in post-therapy samples compared with pre-therapy samples. 4C. Volcano plot
Fig. 5
Fig. 5
Proposed metabolic rewiring (with lipid consumption instead of only glutamine and glucose feeding). This is the first clinical evidence that this metabolic adaptation is used by colorectal cancer cells, after avelumab and ADC therapy, to boost oxidative stress and contribute to cancer progression. Oxidative stress is compensated in IMMETCOLS cluster 3 tumors with anti-oxidative pathways such as pentose-phosphate pathway
See this image and copyright information in PMC

References

    1. Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi: 10.1038/s41591-020-0805-8. - DOI - PubMed
    1. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkMate 142 study. J Clin Oncol. 2022;40(2):161–170. doi: 10.1200/JCO.21.01015. - DOI - PubMed
    1. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA., Jr PD-1 blockade in mismatch repair-deficient locally advanced rectal cancer. N Engl J Med. 2022 doi: 10.1056/NEJMoa2201445. - DOI - PMC - PubMed
    1. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA., Jr KEYNOTE-177 investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi: 10.1056/NEJMoa2017699. - DOI - PubMed
    1. Le DT, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi: 10.1056/nejmoa1500596. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data